Category «APPROVALS 2022»

Carotegrast methyl

Carotegrast methyl Formula C28H26Cl2N4O5 CAS 401905-67-7 Mol weight 569.4358 PMDA APROVED, CAROGRA, カロテグラストメチル ON 2022/3/28 Antiasthmatic, Integrin alpha 4 inhibitor An alpha4 integrin antagonist. 401905-67-7 [RN] L-Phenylalanine, N-(2,6-dichlorobenzoyl)-4-[6-(dimethylamino)-1,4-dihydro-1-methyl-2,4-dioxo-3(2H)-quinazolinyl]-, methyl ester methyl (2S)-2-[(2,6-dichlorophenyl)formamido]-3-{4-[6-(dimethylamino)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl]phenyl}propanoate Methyl N-(2,6-dichlorobenzoyl)-4-[6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydro-3(2H)-quinazolinyl]-L-phenylalaninate Carotegrast Methyl Methyl (2S)-2-(2,6-dichlorobenzamido)-3-{4-[6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]phenyl}propanoate C28H26Cl2N4O5 : 569.44 [401905-67-7] PATENT WO 2008062859 https://patents.google.com/patent/WO2008062859A1/en Step 1 (Method 2): The title compound was prepared starting from 2-amino-5-dimethylamino- …

Risperidone

Risperidone EU APPROVED 2022/2/14, Okedi R-64,766 R-64766 RCN-3028 RCN3028 Risperidone, R-64766, Risperdal M-Tab, Risperdal Consta, Rispolept, Belivon, Risperdal Formula C23H27FN4O2 CAS 106266-06-2 Mol weight 410.4845 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one Product Ingredients INGREDIENT UNII CAS INCHI KEY Risperidone tartrate 0S6B72E3LK 666179-92-6 KSWIOGDSXUFKOC-LREBCSMRSA-N Risperidone CAS Registry Number: 106266-06-2 CAS Name: 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one Manufacturers’ Codes: R-64766 Trademarks: Belivon (Organon); Risperdal (J & J) Molecular Formula: C23H27FN4O2, Molecular Weight: 410.48 Percent …

Lutetium Lu 177 vipivotide tetraxetan

Lutetium Lu 177 vipivotide tetraxetan FDA APPROVED 2022/3/23, Pluvicto To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies Formula C49H65N9O16. Lu. 3H CAS 1703749-62-5 Mol weight 1214.0819 Antineoplastic, Radioactive agent Disease Prostate cancer (PSMA positive) ルテチウム(177Lu)ビピボチドテトラキセタン; UNII-G6UF363ECX, WHO 11429 G6UF363ECX 177Lu-Psma-617 Vipivotide tetraxetan Lu-177 177Lu-Labeled PSMA-617 2-[4-[2-[[4-[[(2S)-1-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]cyclohexyl]methylamino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+) (177Lu)Lutetium 2,2′,2′‘-[10-(2-{[(trans-4-{[(2S)-1-{[(5S)-5-carboxy-5-({[(1S)-1,3-dicarboxypropyl]carbamoyl}amino)pentyl]amino}-3-(2-naphthyl)-1-oxo-2-propanyl]carbamoyl}cyclohexyl)methyl]amino}-2- oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate (non-preferred name) 1983157-55-6 [RN] PSMA-617 LU-177 …

Ganaxolone

Ganaxolone Molecular FormulaC22H36O2 Average mass332.520 Da (3a,5a)-3-Hydroxy-3-methylpregnan-20-one (3α,5α)-3-Hydroxy-3-methylpregnan-20-one 38398-32-2 [RN] 3α-hydroxy-3β-methyl-5α-pregnan-20-one 7476 CCD-1042 FDA APPROVED 3/18/2022, Ztalmy To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder Ganaxolone, sold under the brand name Ztalmy, is a medication used to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).[1][2] Ganaxolone was approved for medical use in the …

Ciltacabtagene autoleucel

Ciltacabtagene autoleucel FDA APPROVED, 2022/2/28, Carvykti Treatment of multiple myeloma JNJ-68284528 LCAR-B38M CAR-T cells Ciltacabtagene autoleucel is a BCMA-directed CAR T-cell therapy used in the treatment of relapsed or refractory multiple myeloma in previously treated patients. U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of …

PACRITINIB

Pacritinib パクリチニブ; Formula C28H32N4O3 CAS 937272-79-2 Mol weight 472.5787 UPDATE FDA APPROVED 2/28/2022, Vonjo To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets A Jak2 inhibitor potentially for the treatment of acute myeloid Leukemia and myelofibrosis. UNII-G22N65IL3O пакритиниб باكريتينيب 帕瑞替尼 ONX-0803; SB-1518 CAS No. 937272-79-2 472.57868 g/mol, C28H32N4O3 S*Bio …

Sutimlimab-jome

(Heavy chain) EVQLVESGGG LVKPGGSLRL SCAASGFTFS NYAMSWVRQA PGKGLEWVAT ISSGGSHTYY LDSVKGRFTI SRDNSKNTLY LQMNSLRAED TALYYCARLF TGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFEGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK (Light chain) QIVLTQSPAT LSLSPGERAT MSCTASSSVS SSYLHWYQQK PGKAPKLWIY STSNLASGVP …

Faricimab-svoa

(A chain) QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARSP NPYYYDSSGY YYPGAFDIWG QGTMVTVSSA SVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS KDSTYSLSST LTLSKADYEK HKVYACEVTH QGLSSPVTKS FNRGECDKTH TCPPCPAPEA AGGPSVFLFP PKPKDTLMAS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLAQDWL NGKEYKCKVS NKALGAPIEK TISKAKGQPR EPQVCTLPPS RDELTKNQVS LSCAVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLVSKLTVDK SRWQQGNVFS CSVMHEALHN AYTQKSLSLS PGK (B chain) EVQLVESGGG LVQPGGSLRL SCAASGYDFT HYGMNWVRQA …

Somatrogon

>Somatrogon amino acid sequence SSSSKAPPPSLPSPSRLPGPSDTPILPQFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFE EAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQF LRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHN DDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGFSSSSKAPPPSLPSPSRLPGPS DTPILPQSSSSKAPPPSLPSPSRLPGPSDTPILPQ Somatrogon CAS: 1663481-09-1 Protein Chemical FormulaC1359H2125N361O420S7 Protein Average Weight30465.1 Da (Aglycosylated) NGENLA, JAPAN PMDA APPROVED 2022/1/20 ソマトロゴン; MOD-4023 Replenisher (somatotoropin) OriginatorModigene DeveloperOPKO Health; Pfizer ClassBiological proteins; Growth hormones; Hormonal replacements; Recombinant proteins Mechanism of ActionHuman growth hormone replacements Orphan Drug StatusYes – Somatotropin deficiency RegisteredSomatotropin deficiency 21 …

Tebentafusp-tebn

Tebentafusp-tebn IMCGP100 UNIIN658GY6L3E CAS number1874157-95-5 FDA APPROVED 1/25/2022, Kimmtrak, To treat unresectable or metastatic uveal melanoma Immunocore Limited T cell receptor α chain (synthetic human) fusion protein with T cell receptor β chain (synthetic human) fusion protein with immunoglobulin, anti-(human CD3 antigen) (synthetic scFv fragment) Protein Sequence Sequence Length: 695, 500, 195 Sequence: 1AIQMTQSPSS LSASVGDRVT ITCRASQDIR NYLNWYQQKP GKAPKLLIYY …